The FDA accepted AbbVie's supplemental Biologics License Application (sBLA) for BOTOX Cosmetic in the treatment of jawline prominence (masseter hypertrophy). The acceptance signals the agency is reviewing the clinical data and moving the indication toward potential approval.
For medspa owners, a new BOTOX indication expands the addressable market and creates a new revenue stream. Masseter treatment is already performed off-label by many practices, but FDA approval legitimizes the indication, supports marketing, and may unlock insurance coverage in some cases. AbbVie will likely support the approval with educational campaigns and Allē rebates tied to masseter volume.